Plenary Session 1: Is There a Future for Intra-Articular Injections in Joint Preservation?

Plenary Session

Date/Time: Thursday, April 29, 2021 - 8:30 AM to 10:30 AM
Log in to Add to My Schedule

Description:

Intra-Articular Injections for Joint Preservation

Clinically recognizable osteoarthritis (osteoarthritis) is late-stage disease that is difficult to reverse. However, symptom and structural progression follow dramatically different timelines for individual patients. At earlier disease states, some of the biological and molecular changes may be reversible. Intra-articular injection of a wide range of pharmacologic, biological, and cellular treatments show promise in delaying OA onset when administered in small animal models early after chemical or surgically induced joint injury. However, this laboratory situation of treating “pre-osteoarthritis” (pre-OA) has few parallels in clinical practice. Because symptoms are poorly correlated with structural changes until late-stage OA in humans, patients are typically unaware of early disease. Consequently, current injection therapies largely provide symptomatic relief of established OA by reducing joint inflammation. Advances in imaging, proteomic, molecular, and mechanical diagnostics may allow for successful treatment of early OA and “pre-OA” where personalized injection therapies based on new developments in cell therapies, molecular biology, and epigenetics may be effective.

 

Abstract(s):

  • 1. SEPARATE REGULATORY VARIANTS AT GDF5-UQCC1 UNDERLIE COMMON KNEE OSTEOARTHRITIS RISK AND DEVELOPMENTAL DYSPLASIA OF THE HIP
    T. D. Capellini1, P. Muthuirulan1, Z. Liu1, A. M. Kiapour2, J. Sieker3, D. E. Maridas4, V. Rosen4, M. Young1; 1Harvard Univ., Cambridge, MA, 2Dept. of Orthopaedic Surgery, Boston Children’s Hosp., Harvard Med. Sch., Boston, MA, 3Dept. of Pathology and Lab. Med., Tufts Med. Ctr., Boston, MA, 4Dept. of Dev.al Biology, Harvard Sch. of Dental Med., Boston, MA

  • 2. EFFICACY OF KRILL OIL IN THE TREATMENT OF KNEE OSTEOARTHRITIS: A 24-WEEK MULTICENTRE RANDOMISED DOUBLE-BLIND CONTROLLED TRIAL
    L. L. Laslett1, L. E. Scheepers1, B. S. Antony1, A. E. Wluka2, C. L. Hill3,4, L. March5,6, H. I. Keen7, P. Otahal1, F. M. Cicuttini2, G. Jones1; 1Menzies Inst. for Med. Res., Univ. of Tasmania, HOBART, Australia, 2Dept. of Epidemiology and Preventive Med., Monash Univ., Melbourne, Australia, 3The Queen Elizabeth Hosp., Adelaide, Australia, 4The Univ. of Adelaide, Adelaide, Australia, 5Kolling Inst., Inst. of Bone and Joint Res., Univ. of Sydney, Sydney, Australia, 6Dept. of Rheumatology, Royal North Shore Hosp., Sydney, Australia, 7Sch. of Med. and Pharmacology, Fiona Stanley Hosp., Perth, Australia

  • 3. INTRAARTICULAR INJECTION OF MM-II, A SUSPENSION OF EMPTY LARGE LIPOSOMES, REDUCES CARTILAGE DEGENERATION IN RAT OSTEOARTHRITIS MODEL
    R. Wechsler; Moebius Med. Inc, Tel Aviv, Israel

  • 4. INTRAMUSCULAR GLUTEAL GLUCOCORTICOID INJECTION VERSUS INTRA-ARTICULAR GLUCOCORTICOID INJECTION IN KNEE OSTEOARTHRITIS: A 24-WEEK MULTICENTER RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL
    Q. Wang1, M. F. Mol1, P. Bos2, D. M. J. Dorleijn3, M. Vis4, J. Gussekloo5, P. J. Bindels1, S. M. Bierma-Zeinstra1, J. Runhaar1; 1Erasmus Med. center, Rotterdam, Netherlands, 2Erasmus Med. center, Dept. of Orthopaedic Surgery, Rotterdam, Netherlands, 3Dept. of Orthopaedic Surgery, Univ. of Groningen, Univ. Med. Ctr. Groningen, Groningen, Netherlands, 4Dept. of Rheumatology, Erasmus Med. center, Rotterdam, Netherlands, 5Leiden Univ. Med. Ctr., Leiden, Netherlands

  • 5. INTRA-ARTICULAR DRUG DEPOTS FOR CONTROLLED RELEASE OF HEAVY CHAIN ONLY ANTIBODIES BLOCKING JOINT INFLAMMATION
    M. Koerselman1, K. Warmink2, N. M. Korthagen2, P. M. van Midwoud3, T. Verrips4, H. Weinans2, M. Karperien1; 1Univ. of Twente, Enschede, Netherlands, 2UMC Utrecht, Utrecht, Netherlands, 3InnoCore Pharmaceuticals, Groningen, Netherlands, 4Orthros Med., Raalte, Netherlands

  • 6. THE “PLACEBO EFFECT” IN OSTEOARTHRITIS CLINICAL TRIALS: CHALLENGING THE NARRATIVE
    E. Ashbeck1, E. J. Bedrick2, C. K. Kwoh3; 1The Univ. of Arizona Arthritis Ctr., Tucson, AZ, 2Dept. of Epidemiology and Biostatistics, Univ. of Arizona, Tucson, AZ, 3Div. of Rheumatology, Univ. of Arizona, Tucson, AZ

Speaker(s):